Pharsight

Xeljanz generic

Xeljanz is an immunosuppressive drug owned by Pf Prism Cv. The active ingredient in Xeljanz is tofacitinib citrate. The drug was first authorised for market use on 06 November, 2012 and it is available in tablet; oral dosage forms.

When will Xeljanz generic be available?

The generic version of Xeljanz is expected to be available after 08 December, 2025. The patent USRE41783 titled 'Pyrrolo[2,3-D]pyrimidine compounds' affecting the generic release of Xeljanz expires on this date.

Xeljanz uses

Xeljanz is primarily used in the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. tofacitinib citrate, the active ingredient, works by inhibiting Janus kinases, enzymes that play a crucial role in the immune response.

Xeljanz patent expiration

Xeljanz holds a total of two drug patents, US6965027 and USRE41783. The latter is the last to expire on 08 December, 2025, paving the way for the potential release of the Xeljanz generic. Below is the detail of the patent:

EPO Oppostions filed on Xeljanz

Xeljanz dosage

Want to ask something?